<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734487</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001749</org_study_id>
    <secondary_id>Genentech FVF4400</secondary_id>
    <nct_id>NCT00734487</nct_id>
  </id_info>
  <brief_title>AREDS 2 Ancillary Spectral Domain Optical Coherence Tomography Study</brief_title>
  <acronym>A2ASDOCT</acronym>
  <official_title>Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify whether changes in age-related macular degeneration
      (AMD) over time as seen with spectral domain optical coherence tomography (SDOCT) imaging,
      can be used to predict vision loss and the advancement of AMD in people at moderate to high
      risk for progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to identify whether SDOCT patterns such as: drusen
      size, OCT reflectivity within drusen, photoreceptor (PR)change over drusen, microfoci of
      subretinal fluid (SRF), or retinal thickening are predictive of vision loss, progression of
      drusen, progression of photoreceptor loss over drusen, development of choroidal
      neovascularization (CNV), or development of geographic atrophy (GA).

      The secondary objectives of this study are:

        1. To define the relationship between SDOCT imaging, autofluorescence (AF)imaging, and
           color photographic or other fundus imaging of AREDS 2 patients in both a cross-sectional
           study of baseline data and a longitudinal study in data collected over the 5 year AREDS
           2 study.

        2. To compare the extent of geographic atrophy on SDOCT versus color photographs and
           autofluorescence.

        3. To evaluate whether the SDOCT outcome measures differ significantly between AREDS 2
           patients randomized to different oral supplements in the AREDS2.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measures are the percent of eyes developing CNV, mean change in visual acuity, and change in drusen volume, area of GA and photoreceptor layer thickness from SDOCT centered on the fovea.</measure>
    <time_frame>2 years and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drusen area measured from SDOCT versus from color fundus photographs. Mean change in drusen area reproducibility of measurements using these techniques.</measure>
    <time_frame>2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grading of drusen type, presence or absence of fluid, photoreceptor loss or retinal thickening from SDOCT versus from color fundus photographs at each timepoint.</measure>
    <time_frame>2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between SDOCT imaging and autofluorescence imaging and onset of geographic atrophy.</measure>
    <time_frame>2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of area of GA from SDOCT images versus color fundus photos versus AF images.</measure>
    <time_frame>2 years and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate whether the SDOCT outcome measures differ significantly between AREDS 2 patients randomized to different oral supplements in the AREDS2.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">470</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>1. AREDS2 subjects</arm_group_label>
    <description>Subjects enrolled in the AREDS2 clinical trial with a diagnosis of age-related macular degeneration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Controls</arm_group_label>
    <description>Age-matched subjects without retinal pathology</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The A2A SDOCT study will recruit AMD subjects from the AREDS 2 study population at 4 AREDS
        2 Study Centers. Controls will be recruited from Duke University Eye Center and Emory
        University.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        AMD subjects and controls

          -  Men and women between the ages of 50 and 85 years

        AMD subjects

          -  Enrollment in the AREDS 2 trial;

          -  Macular status ranges from large drusen in both eyes or large drusen in one eye and
             advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye

        Exclusion Criteria:

          -  Ocular media not clear enough to allow good fundus photography.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia A Toth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Legacy Devers Eye Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baker Hubbard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Eye Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wai T Wong, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Eye Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Devers Eye Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.areds2.org</url>
    <description>Age-Related Eye Disease Study 2</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00345176?term=AREDS2&amp;rank=1</url>
    <description>Age-Related Eye Disease Study 2 (AREDS2) registry at ClinicalTrials.gov</description>
  </link>
  <reference>
    <citation>Folgar FA, Yuan EL, Sevilla MB, Chiu SJ, Farsiu S, Chew EY, Toth CA; Age Related Eye Disease Study 2 Ancillary Spectral-Domain Optical Coherence Tomography Study Group. Drusen Volume and Retinal Pigment Epithelium Abnormal Thinning Volume Predict 2-Year Progression of Age-Related Macular Degeneration. Ophthalmology. 2016 Jan;123(1):39-50.e1. doi: 10.1016/j.ophtha.2015.09.016. Epub 2015 Nov 12.</citation>
    <PMID>26578448</PMID>
  </reference>
  <reference>
    <citation>Farsiu S, Chiu SJ, O'Connell RV, Folgar FA, Yuan E, Izatt JA, Toth CA; Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Quantitative classification of eyes with and without intermediate age-related macular degeneration using optical coherence tomography. Ophthalmology. 2014 Jan;121(1):162-72. doi: 10.1016/j.ophtha.2013.07.013. Epub 2013 Aug 29.</citation>
    <PMID>23993787</PMID>
  </reference>
  <reference>
    <citation>Folgar FA, Chow JH, Farsiu S, Wong WT, Schuman SG, O'Connell RV, Winter KP, Chew EY, Hwang TS, Srivastava SK, Harrington MW, Clemons TE, Toth CA. Spatial correlation between hyperpigmentary changes on color fundus photography and hyperreflective foci on SDOCT in intermediate AMD. Invest Ophthalmol Vis Sci. 2012 Jul 9;53(8):4626-33. doi: 10.1167/iovs.12-9813.</citation>
    <PMID>22589439</PMID>
  </reference>
  <reference>
    <citation>Chiu SJ, Izatt JA, O'Connell RV, Winter KP, Toth CA, Farsiu S. Validated automatic segmentation of AMD pathology including drusen and geographic atrophy in SD-OCT images. Invest Ophthalmol Vis Sci. 2012 Jan 5;53(1):53-61. doi: 10.1167/iovs.11-7640.</citation>
    <PMID>22039246</PMID>
  </reference>
  <reference>
    <citation>Yiu G, Pecen P, Sarin N, Chiu SJ, Farsiu S, Mruthyunjaya P, Toth CA. Characterization of the choroid-scleral junction and suprachoroidal layer in healthy individuals on enhanced-depth imaging optical coherence tomography. JAMA Ophthalmol. 2014 Feb;132(2):174-81. doi: 10.1001/jamaophthalmol.2013.7288.</citation>
    <PMID>24336985</PMID>
  </reference>
  <reference>
    <citation>Yiu G, Chiu SJ, Petrou PA, Stinnett S, Sarin N, Farsiu S, Chew EY, Wong WT, Toth CA. Relationship of central choroidal thickness with age-related macular degeneration status. Am J Ophthalmol. 2015 Apr;159(4):617-26. doi: 10.1016/j.ajo.2014.12.010. Epub 2014 Dec 17.</citation>
    <PMID>25526948</PMID>
  </reference>
  <reference>
    <citation>Christenbury JG, Folgar FA, O'Connell RV, Chiu SJ, Farsiu S, Toth CA; Age-related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology. 2013 May;120(5):1038-45. doi: 10.1016/j.ophtha.2012.10.018. Epub 2013 Jan 23.</citation>
    <PMID>23352193</PMID>
  </reference>
  <reference>
    <citation>Leuschen JN, Schuman SG, Winter KP, McCall MN, Wong WT, Chew EY, Hwang T, Srivastava S, Sarin N, Clemons T, Harrington M, Toth CA. Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration. Ophthalmology. 2013 Jan;120(1):140-50. doi: 10.1016/j.ophtha.2012.07.004. Epub 2012 Sep 8.</citation>
    <PMID>22968145</PMID>
  </reference>
  <reference>
    <citation>Chiu SJ, Li XT, Nicholas P, Toth CA, Izatt JA, Farsiu S. Automatic segmentation of seven retinal layers in SDOCT images congruent with expert manual segmentation. Opt Express. 2010 Aug 30;18(18):19413-28. doi: 10.1364/OE.18.019413.</citation>
    <PMID>20940837</PMID>
  </reference>
  <reference>
    <citation>Jain N, Farsiu S, Khanifar AA, Bearelly S, Smith RT, Izatt JA, Toth CA. Quantitative comparison of drusen segmented on SD-OCT versus drusen delineated on color fundus photographs. Invest Ophthalmol Vis Sci. 2010 Oct;51(10):4875-83. doi: 10.1167/iovs.09-4962. Epub 2010 Apr 14.</citation>
    <PMID>20393117</PMID>
  </reference>
  <reference>
    <citation>Veerappan M, El-Hage-Sleiman AM, Tai V, Chiu SJ, Winter KP, Stinnett SS, Hwang TS, Hubbard GB 3rd, Michelson M, Gunther R, Wong WT, Chew EY, Toth CA; Age-related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Optical Coherence Tomography Reflective Drusen Substructures Predict Progression to Geographic Atrophy in Age-related Macular Degeneration. Ophthalmology. 2016 Dec;123(12):2554-2570. doi: 10.1016/j.ophtha.2016.08.047. Epub 2016 Oct 25.</citation>
    <PMID>27793356</PMID>
  </reference>
  <reference>
    <citation>Sleiman K, Veerappan M, Winter KP, McCall MN, Yiu G, Farsiu S, Chew EY, Clemons T, Toth CA; Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study Group. Optical Coherence Tomography Predictors of Risk for Progression to Non-Neovascular Atrophic Age-Related Macular Degeneration. Ophthalmology. 2017 Dec;124(12):1764-1777. doi: 10.1016/j.ophtha.2017.06.032. Epub 2017 Aug 26.</citation>
    <PMID>28847641</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spectral Domain Optical Coherence Tomography</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>AREDS2</keyword>
  <keyword>AMD</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Drusen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All findings resulting from the A2A SDOCT study will be prepared for publication in peer-reviewed journals and posted on PubMed Central once accepted.
We are supportive of efforts by publishers and professional societies to develop technologies for on-line publishing of entire experimental datasets. We will archive experimental results and findings from the proposed project for at least the duration of the project, and make the underlying datasets available to other researchers upon request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

